ATLAS fair value
$2.36
Below fair value · 50% discount
Biote stock price today, ATLAS forecast and fair value
Healthcare · Medical Care Facilities · NASDAQ
Prices as of Oct 27, 2026 · USD
$2.36
Below fair value · 50% discount
46%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS estimates Biote's fair value at about $2.36 per share (reasonable range: $1.99 to $2.76). At $1.19, the stock trades 50% below it.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is low. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Biote a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $1.03 and $1.33; in 9 out of 10, between $0.82 and $1.66. Estimated annual volatility is 77%.
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Biote sits below fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks BTMD has traded between $1.00 and $2.98. Today it is 60.2% below that high and 19% above its low.
On the business: revenue fell 2.5% year over year; net margin is 16.4%; it trades at 6.7 times earnings.
Its beta is 1.61: it tends to move more than the market, both up and down.
Biote Corp. Class A Common Stock is the equity of Biote Corp., a healthcare company focused on hormone optimization and practice-building services for medical providers.
Want to see everything about Biote?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
About $2.36 per share according to ATLAS (reasonable range: $1.99 to $2.76). With the stock at $1.19, it is 50% below it.
46%: close to a coin flip. In half of the simulated outcomes, BTMD ends the month between $1.03 and $1.33.
Biote's market capitalization is $39.0M. Its price-to-earnings (P/E) ratio is 6.7: you pay $6.7 for each $1 of yearly earnings.
ATLAS estimates annual volatility at 77%. In a typical month, half of the outcomes end between $1.03 and $1.33.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy